Carmell Corp. (CTCX): Rasio utang marang kapitalisasi buku

Logo korporat perusahaan Carmell Corp. (CTCX)

Business diversification from bone regeneration to aesthetics reduces Carmell Corporation (CTCX) dependence on regulators, which is further complemented by innovative plasma materials for rapid tissue healing. The debt-to-equity ratio confirms financial stability, with the indicator standing at 0.00. Management is currently adapting its strategy toward bio-aesthetics, while the market cautiously awaits the commercialization results of new products.

CTCX Carmell Therapeutics: Utang marang nilai buku ing interval 21.02.2024 - 10.03.2025
Produk sing diprodhuksi Carmell Corp

This ratio measures the degree of business dependence on borrowed capital relative to its book value. For Carmell Corporation (CTCX), which is developing a high-tech ecosystem of regenerative biomaterials, the leverage balance is critical when scaling R&D. By analyzing the current structure of liabilities to book capitalization, an investor assesses default risk against the potential for profitability growth. Moderate leverage confirms the financial stability of this biotech leader, ensuring asset preservation during its expansion into aesthetic medicine.

Analisis pesaing

Utang-utang marang kapitalisasi buku ASND (Ascendis Pharma A/S)|Utang-utang marang kapitalisasi buku madrigalpharma.com MDGL|CORT - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik RYTM (Rhythm Pharma)|Akero Therapeutics Inc (AKRO) - Rasio utang marang kapitalisasi buku|Utang marang nilai buku Metsera Therapeutics|MLTX (MoonLake Immunotherapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku crinetics.com|Utang marang nilai buku NAMS (NewAmsterdam Pharma Company N.V.)|SLNO (Soleno Therapeutics Inc) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku Amicus Pharma FOLD|ETNB - Utang marang nilai buku|Agios Pharmaceuticals - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku structuretx.com|MDXG (MiMedx) - Utang marang nilai buku|RZLT: Utang marang modal buku|LXRX (Lexicon Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MBX Corp|Utang-utang marang kapitalisasi buku ALT|Rasio utang marang kapitalisasi buku AARD (aardvarktherapeutics.com)|Rasio utang marang kapitalisasi buku Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Utang-utang marang nilai buku|BMEA - Rasio utang marang kapitalisasi buku|QNCX: Rasio utang marang kapitalisasi buku|GUTS: Utang-utang marang kapitalisasi buku|VTVT - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Agape ATP Corp|Pluri Inc (PLUR) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Synlogic, Inc. (SYBX)|Utang marang nilai buku Lipocine Corporation LPCN|Utang-utang marang kapitalisasi buku MTNB (Matinas BioPharma Holdings)|SPRB - Utang marang nilai buku|Galecto - Utang-utang marang kapitalisasi buku|LUMO - Utang-utang marang kapitalisasi buku|Organovo Holdings Inc (ONVO) - Rasio utang marang kapitalisasi buku|Radius Pharmaceuticals - Rasio utang marang aset resik